In addition to their roles in sensitizing melanoma cells to BRAFi, the SRC inhibitors Bos and Das, even at low doses (1 μM), prevented the invasive capacity of wild‐type AhR melanoma cells (red) in three‐dimensional spheroid assays (Fig 5B). Here, SRC is linked to melanoma.